Nim­bus clinch­es $125M raise via big donor-backed pri­vate fi­nanc­ing round fol­low­ing Bris­tol My­er­s' TYK2 ap­proval

More than a year af­ter rais­ing $105 mil­lion in a pri­vate fi­nanc­ing round, Nim­bus Ther­a­peu­tics is back with its next haul as it con­sid­ers its next steps, thanks to Bris­tol My­ers Squibb.

The com­pu­ta­tion­al chem­istry biotech, co-found­ed in 2009 by VC Bruce Booth, an­nounced its most re­cent fi­nanc­ing round Mon­day worth $125 mil­lion — Nim­bus’ fifth big fi­nanc­ing in the last sev­en years.

CEO Jeb Keiper tells End­points News that the fi­nanc­ing will sup­port Nim­bus’ en­tire pipeline, in­clud­ing its lead can­di­dates and pre­clin­i­cal ef­forts. At the biotech’s fore­front is its TYK2 pro­gram, which is cur­rent­ly in a Phase IIb study for pso­ri­a­sis. And ac­cord­ing to Keiper, the biotech is run­ning hot in its at­tempt to get its TYK2 drug past the reg­u­la­to­ry fin­ish line — cour­tesy of Bris­tol My­ers beat­ing them to the punch with its own TYK2 drug just last week, now brand­ed as So­tyk­tu, for pso­ri­a­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER